Clinical Trials
8 trialsNCT02955940 2025-12-17
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
Phase 2 Active not recruiting
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT05440942 2025-06-05
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
University of Miami
Phase 1 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02117479 2019-03-26
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Incyte Corporation
Phase 3 Terminated
NCT02119663 2018-02-13
A Study of Ruxolitinib in Pancreatic Cancer Patients
Incyte Corporation
Phase 3 Terminated
NCT01423604 2018-02-12
RECAP
Incyte Corporation
Phase 2 Completed
NCT01822756 2018-02-12
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated